

RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer



Open Access This file is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. In the cases where the authors are anonymous, such as is the case for the reports of anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear attribution to the source work. The images or other third party material in this file are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

REVIEWERS' COMMENTS

Reviewer #1 (Remarks to the Author):

The authors have addressed my criticisms. This revised manuscript has improved substantially and in my opinion, should be considered for publication in Nature Communications.

Reviewer #2 (Remarks to the Author):

The authors have responded to my initial comments and questions well and I have no further issues with the manuscript.

Reviewer #3 (Remarks to the Author):

In their revised version, the authors have convincingly addressed my concerns. New data is shown that supports the tumor-specific effects after Srsf1 reduction and Deltarasin/Pladienolide B treatment, which had also been remarked by reviewer 1. Furthermore, the motivation for analyzing heterozygous Srsf1 mutants is now explained clearer. The CRISPR screening data has been properly replicated as requested and the statistical analysis and reporting of this data has substantially improved. Together, I have no further comments. I thank the authors for their careful revision and congratulate them on this important work.

Reviewer #1 (Remarks to the Author):

The authors have addressed my criticisms. This revised manuscript has improved substantially and in my opinion, should be considered for publication in Nature Communications.

Reviewer #2 (Remarks to the Author):

The authors have responded to my initial comments and questions well and I have no further issues with the manuscript.

Reviewer #3 (Remarks to the Author):

In their revised version, the authors have convincingly addressed my concerns. New data is shown that supports the tumor-specific effects after Srsf1 reduction and Deltarasin/Pladienolide B treatment, which had also been remarked by reviewer 1. Furthermore, the motivation for analyzing heterozygous Srsf1 mutants is now explained clearer. The CRISPR screening data has been properly replicated as requested and the statistical analysis and reporting of this data has substantially improved. Together, I have no further comments. I thank the authors for their careful revision and congratulate them on this important work.

We thank the reviewers for taking the time to review our manuscript and their supportive comments to recommend publication.